Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 3, 2015, Pages 147-154

  Nguyen, Douglas L ^a   Flores, Sarah ^a   Sassi, Kareem ^a   Bechtold, Matthew L ^b   Nguyen, Emily T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti TNF; Crohn s disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

6 THIOURIC ACID; ALDEHYDE OXIDASE; ALLOPURINOL; C REACTIVE PROTEIN; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; XANTHINE DEHYDROGENASE;

ARTHRALGIA; DNA METHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HEADACHE; HUMAN; INFLAMMATORY BOWEL DISEASE; METABOLITE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW;

EID: 84930515963     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315579621     Document Type: Review

References (50)

1. Afif W. Loftus E. Faubion W. Kane S. Bruining D. Hanson K. Sandborn W. et al. (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105: 1133–1139.
2. Baert F. Drobne D. Ballet V. Gils A. Vande Casteele N. Hauenstein S. et al. (2013) Trough levels and antidrug antibodies predict safety and success of restarting infliximab after a long drug holiday. Gastroenterology 144: S-91–S-92.
3. Baert F. Noman M. Vermeire S. van Assche G. D'Haens G. Carbonez A. et al. (2003) Influence of immunogenicity on the long term efficacy of Infliximab in Crohn's disease. N Engl J Med 348: 601–608.
4. Ben-Horin S. Chowers Y. (2011) Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 33: 987–995.
5. Ben-Horin S. Goldstein I. Fudim E. Picard O. Yerushalmi Z. Barshack I. et al. (2009) Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 58: 396–403.
6. Ben-Horin S. Kopylov U. Chowers Y. (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13: 24–30.
7. Billioud V. Sandborn W. Peyrin-Biroulet L. (2011) Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 106: 674–684.
8. Chiu Y. Rubin D. Vermeire S. Louis E. Robinson A. Lomax K. et al. (2013) Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 19: 1112–1122.
9. Colombel J. Sandborn W. Reinisch W. Mantzaris G. Kournbluth A. Rachmilewitz D. et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383–1395.
10. Colombel J. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Panaccione R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65.
11. Deepak P. Stobaugh D. Ehrenpreis E. (2013) Infectious complications of TNA-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 22: 269–276
12. D'Haens G. Baert F. van Assche G. Caenepeel P. Vergauwe P. Tuynman H. et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 371: 660–667.
13. Dubinsky M. Lamothe S. Yang H. Targan S. Sinnett D. Theoret Y. et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705–713.
14. Dulai P. Siegel C. Colombel J. Sandborn W. Peyrin-Biroulet L. (2014) Systematic review: monotherapy with antitumor necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut 63: 1843–1853.
15. Farrell R. Alsahli M. Jeen Y. (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124: 917–924.
16. Feagan B. McDonald J. Panaccione R. Enns R. Bernstein C. Ponich T. et al. (2014) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 146: 681–688.
17. Feagan B. Singh S. Lockton S. Hauenstein S. Ohrmund L. Croner L. et al. (2012) Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterology 142: S-114.
18. Gisbert J. Panes J. (2009) Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 104: 760–767.
19. Hanauer S. Feagan B. Lichenstein G. Mayer L. Schreiber S. Colombel J. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet 359: 1541–1549.
20. Hanauer S. Sandborn W. Rutgeerts P. Fedorak R. Lukas M. MacIntosh D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323–333.
21. Hanauer S. Wagner C. Bala M. Mayer L. Travers S. Diamond R. et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542–553.
22. Jones J. Kaplan G. Peyrin-Biroulet L. Baidoo L. Devlin S. Melmed G. et al. (2013) Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data. Gastroenterology 144: S-179.
23. Karmiris K. Paintaud G. Noman M. Magdelaine-Beuzelin C. Ferrante M. Degenne D. et al. (2009) Influence of trough serum levels and immunogenicity on long-term outome of adalimumab therapy in Crohn's disease. Gastroenterology 137: 1628–1640.
24. Kopylov U. Mazor Y. Yavzori M. Fudim E. Katz L. Coscas D. et al. (2012) Clinical utility of antihuman labda chain-based enzyme-linked immunosorbent assay (ELIZA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 18: 1628–1633.
25. Lemann M. Mary J. Duclos B. Veyrac M. Dupas J. Delchier J. et al. (2006) Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130: 1054–1061.
26. Mackey A. Green L. Liang L. Dinndorf P. Avigan M. (2007) Hepatosplenic T cell lymphoma associated with Infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 265–267.
27. Maser E. Villela R. Silverberg M. Greenberg G. (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4: 1248–1254.
28. Mostafa N. Eckert D. Pradham R. Mensing S. Robinson A. Sandborn W. et al. (2013) Exposure-efficacy relationship for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis. Gastroenterology 144: S225–S226.
29. Murthy S. Kevans D. Seow C. Newman A. Steinhart A. Silverberg M. et al. (2012) Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis. Gastroenterology 142: S-388.
30. Nanda K. Cheifetz A. Moss A. (2013) Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 108: 40–47.
31. Nguyen D. Solaimani P. Nguyen E. Jamal M. Bechtold M. (2014). Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: a meta-analysis. Eur J Gastroenterol Hepatol 26: 1152–1159.
32. Osterman M. Kundu R. Lichtenstein G. Lewis J. (2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130: 1047–1053.
33. Peyrin-Biroulet L. Lemann M. (2011) Remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 33: 870–879.
34. Reinisch W. Feagan B. Rutgeerts P. Adedokun O. Comillie F. Diamond R. et al. (2012) Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gatroenterology 142: S-114.
35. Sandborn W. Feagan B. Stoinov S. Honiball P. Rutgeerts P. Mason D. et al. (2007 a) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228–238.
36. Sandborn W. Hanauer S. Rutgeerts P. Fedorak R. Lukas M. MacIntosh D. et al. (2007 b) Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56: 1232–1239.
37. Sands B. Anderson F. Bernstein C. Chey W. Feagan B. Fedorak R. et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876–885.
38. Schreiber S. Khaliq-Kareemi M. Lawrance I.C. Thomsen O.O. Hanauer S.B. McColm J. et al. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239–250.
39. Selvaraj S. Chairez E. Wilson L. Lazarev M. Bass E. Hutfless S. (2013) Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma. Syst Rev 2: 53.
40. Siegel C. Marden S. Persing S. Larson R. Sands B. (2009) Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 7: 874–881.
41. Steenholdt C. Bendtzen K. Brynskov J. Thomsen O. Ainsworth M. (2014 a) Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 109: 1055–1064.
42. Steenholdt C. Brynskov J. Thomsen O.O. Munck L. Fallingborg J. Christensen L. et al. (2014 b) Individualized therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomized controlled trial. Gut 63: 919–927.
43. van Assche G. Magdelaine-Beuzelin C. D'Haens G. Baert F. Noman M. Vermeire S. et al. (2008) Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134: 1861–1868.
44. Vande Casteele N. Compernolle G. Ballet V. van Assche G. Gils A. Vermeire S. et al. (2012) Results on the optimization phase of the prospective controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial. Gastroenterology 142: S-211–S-212.
45. Vande Casteele N. Gills A. Singh S. Ohrmund L. Hauenstein S. Rutgeerts P. et al. (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108: 962–971.
46. Velayos F. Kahn J. Sandborn W. Feagan B. (2013 a) A test-based strategy is more cost effective than empiric dose-escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 11: 654–666.
47. Velayos F. Sheibani S. Lockton S. Hauenstein S. Singh S. Terdiman J. et al. (2013 b) Prevelance of antibodies to adalimumab and correlation between ATA and low serum drug concentration on CRP an clinical symptoms in a prospective sample of IBD patients. Gastroenterology 144: S-91.
48. West R. Zelinkova Z. Wolbink G. Kuipers E. Stokkers P. van der Woude C. (2008) Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 28: 1122–1126.
49. Yarur A. Deshpande A. Sussman D. Hauenstein S. Lockton S. Barkin J. et al. (2013) Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology 144: S-774–S-775.
50. Yaryr A. Kubiliun M. Drake K. Hauenstein S. Barkin J. Sussman D. et al. (2014) Higher 6-thioguanine nucleotide concentrations are associated with higher trough levels of infliximab in patients on combination therapy. Gastroenterology 146: S134–S135.